{"organizations": [], "uuid": "6f7a4ffe0bad9ce1dde13a7dfcff6b5df91cb4ea", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180412.html", "section_title": "Archive News &amp; Video for Thursday, 12 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-heidelberg-pharma-q1-net-loss-wide/brief-heidelberg-pharma-q1-net-loss-widens-to-2-4-million-euros-idUSFWN1RP00Z", "country": "US", "domain_rank": 408, "title": "BRIEF-Heidelberg Pharma Q1 Net Loss Widens To 2.4 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-12T13:10:00.000+03:00", "replies_count": 0, "uuid": "6f7a4ffe0bad9ce1dde13a7dfcff6b5df91cb4ea"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-heidelberg-pharma-q1-net-loss-wide/brief-heidelberg-pharma-q1-net-loss-widens-to-2-4-million-euros-idUSFWN1RP00Z", "ord_in_thread": 0, "title": "BRIEF-Heidelberg Pharma Q1 Net Loss Widens To 2.4 Million Euros", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-heidelberg pharma", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "heidelberg pharma ag", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12 (Reuters) - Heidelberg Pharma AG:\n* OUTLOOK 2018: INCREASE INVESTMENTS IN PROPRIETARY ATAC PIPELINE FOR PREPARATION OF CLINICAL DEVELOPMENT\n* Q1 SALES REVENUE AND INCOME TOTALING EUR 0.7 MILLION (PREVIOUS YEAR: EUR 0.6 MILLION)\n* NET LOSS FOR FIRST THREE MONTHS OF FISCAL YEAR INCREASED TO EUR 2.4 MILLION (PREVIOUS YEAR: EUR 2.0 MILLION)\n* FINANCIAL GUIDANCE REMAINS UNCHANGED COMPARED TO THAT PROVIDED ON 22 MARCH 2018\n* Q1 OPERATING EXPENSES INCLUDING DEPRECIATION AND AMORTIZATION AMOUNTED TO EUR 3.1 MILLION\n* EXPECTS TO REQUIRE FUNDS OF EUR 13.0 MILLION TO EUR 17.0 MILLION IN 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-12T13:10:00.000+03:00", "crawled": "2018-04-13T18:04:25.002+03:00", "highlightTitle": ""}